drugset / Trial / NCT05815173
Ladarixin With Sotorasib in Advanced NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2023-08-01
- Primary completion
- 2027-08
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ladarixin | Unknown | 200 mg | — |
| Subject | Ladarixin | Unknown | 300 mg | — |
| Subject | Sotorasib | Small molecule | 960 mg | Oral |